OmniAb因与礼来达成一笔价值高达3.7亿美元的药物研发协议而股价上涨

路透中文
Aug 17
BUZZ-OmniAb因与<a href="https://laohu8.com/S/LLY">礼来</a>达成一笔价值高达3.7亿美元的药物研发协议而股价上涨

8月17日 - ** 生物技术公司OmniAb(OABI.O)的股价在盘前交易中上涨24%,至4.27美元

** 该公司表示已与礼来公司(LLY.N)就一项新的离子通道药物研发项目签署了全球合作与许可协议

** 称将获得一笔预付款,并有资格获得最高3.7亿美元的研发及商业化里程碑付款

** 离子通道是一种有助于控制细胞内信号的蛋白质,是多种疾病治疗的靶点

** OmniAb表示,此次合作将利用其抗体发现平台及离子通道筛选专业技术

** 协议还包括基于全球净销售额的分级专利使用费;治疗靶点和药物类型未予披露

** 截至上一交易日收盘,该公司股价年内累计上涨约83%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10